Clinical Trial Update: EPI-7386 in Combination with Enzalutamide Compared with Enzalutamide Alone in Subjects with MCRPC [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating EPI-7386 in combination with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer was terminat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• EPI-7386
• Enzalutamide (enzalutamide)

Snippet

Sponsor: ESSA Pharmaceuticals | Conditions: Prostate Cancer | Phase 1, Phase 2 | Status: TERMINATED